Skip to main content

Table 10 Top 20 drugs corresponding to subtype 9

From: Computationally repurposing drugs for breast cancer subtypes using a network-based approach

Rank

Drug

Dosage (μm)

Treatment time (h)

Score

Drug type

References

1

Rupatadine

0.04

24

− 0.72

Approved

 

2

Ruxolitinib

10

24

− 0.69

Approved

[51, 52]

3

Raloxifene

0.04

24

− 0.65

Approved

[99]

4

Emtricitabine

10

24

− 0.65

Approved

[114]

5

L-690330

10

24

− 0.65

Investigational

 

6

Tepotinib

10

24

− 0.64

Approved

[115]

7

Amiprilose

0.04

24

− 0.63

Experimental

 

8

TG-100801

0.04

24

− 0.61

Investigational

 

9

MG-132

20

24

− 0.61

Experimental

[111]

10

Belinostat

0.04

24

− 0.59

Approved

[116, 117]

11

Bromocriptine

0.04

24

− 0.59

Approved

[63]

12

Vidarabine

0.04

24

− 0.59

Approved

 

13

Ranolazine

0.04

24

− 0.58

Approved

[78]

14

Lisinopril

0.04

24

− 0.58

Approved

[107]

15

PD-173074

10

24

− 0.57

Experimental

[88]

16

Vilazodone

10

24

− 0.57

Approved

[118]

17

Dexamethasone

0.04

24

− 0.57

Approved

[119, 120]

18

Semaxanib

0.04

24

− 0.57

Investigational

[79]

19

Mocetinostat

0.04

24

− 0.57

Investigational

[121]

20

Fingolimod

0.04

24

− 0.56

Approved

[82]